# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to ...
Guggenheim analyst Evan Wang maintains Valneva (NASDAQ:VALN) with a Buy and lowers the price target from $18 to $17.
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
Updated FY 2024 guidance Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an ...
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.
Reimbursements of the first $100 million tranche will now start in January 2026 instead of July 2024. Maturity of this first tr...